Stonepine Capital Management, LLC holds a focused book of 72 stocks worth $131.4M as of Q2 2026 (disclosed Aug 17, 2026, a ~48-day 13F lag). This quarter they opened Eloxx Pharmaceuticals Inc and trimmed Evolus Inc. Their largest long position is Verastem Inc at 10% of the equity book. They also disclosed $45.9M in call options (bullish), shown separately below and excluded from the equity book. Cloning the disclosed picks since 2024 would be +59% (+25.4%/yr). That is a simulation of the disclosed long book, not audited returns.
Following at the filing date actually beat the quarter-end book by 30.5 points over this window.
Growth of $10,000 cloning Stonepine Capital Management, LLC's disclosed long 13F book, rebalanced on each filing date (so it reflects each quarter's actual reporting lag, ~48 days for the latest filing, with no look-ahead), total-return basis (dividends reinvested), derived from end-of-day prices. “Their reported book” values the same picks from quarter-end, before they were public. S&P 500 is SPY total return over the same window. Excludes shorts, cash, options and non-13F holdings. Not investment advice.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
94% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as Stonepine Capital Management, LLC
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| UBS Group AG | 77 / 72 | $223.5M |
| GEODE CAPITAL MANAGEMENT, LLC | 72 / 72 | $804.5M |
| MORGAN STANLEY | 65 / 72 | $437.6M |
| VANGUARD CAPITAL MANAGEMENT LLC | 61 / 72 | $962.0M |
| VANGUARD FIDUCIARY TRUST CO | 61 / 72 | $138.9M |
| Tower Research Capital LLC (TRC) | 61 / 72 | $1.8M |
| BlackRock, Inc. | 60 / 72 | $1.8B |
| NORTHERN TRUST CORP | 58 / 72 | $147.5M |
Ranked by how many of Stonepine Capital Management, LLC's top 72 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Verastem Inc COM NEW | $12.8M | 3.35M | 9.7% | ▲+1.4% Added · +47K sh | |
| 2 | Evolus Inc COM | $11.0M | 1.59M | 8.4% | ▼−9.6% Reduced · −169K sh | |
| 3 | Tenax Therapeutics Inc COM NEW | $9.6M | 660.0K | 7.3% | ▼−32% Reduced · −315K sh | |
| 4 | Nektar Therapeutics COM NEW | $8.4M | 120.7K | 6.4% | ▲+42% Added · +36K sh | |
| 5 | Adma Biologics Inc COM | $6.2M | 740.0K | 4.7% | —Held | |
| 6 | Camp4 Therapeutics Corp COM 13469V AB 4 CAMTEK LTD NOTE 12/0 | $6.1M | 1.39M | 4.6% | —Held | |
| 7 | Eloxx Pharmaceuticals Inc COM NEW | $5.5M | 397.2K | 4.2% | ▲New New position | |
| 8 | Kazia Therapeutics Ltd SPONSORED ADS | $4.9M | 345.2K | 3.7% | —Held | |
| 9 | Indivior Pharmaceuticals Inc COM | $4.1M | 100.0K | 3.1% | ▲New New position | |
| 10 | Corbus Pharmaceuticals Hldgs COM NEW | $4.0M | 425.0K | 3.0% | ▲+11% Added · +42K sh | |
| 11 | Satellos Bioscience Inc COM | $3.7M | 491.6K | 2.8% | ▲+392% Added · +392K sh | |
| 12 | Zevra Therapeutics Inc COM NEW | $3.7M | 258.7K | 2.8% | ▼−46% Reduced · −221K sh | |
| 13 | Abeona Therapeutics Inc COM NEW | $3.4M | 557.3K | 2.6% | ▼−25% Reduced · −189K sh | |
| 14 | Edesa Biotech Inc COM NEW | $3.2M | 456.4K | 2.4% | ▲15× Added · +426K sh | |
| 15 | Cabaletta Bio Inc COM | $2.9M | 917.1K | 2.2% | ▲18× Added · +867K sh | |
| 16 | An2 Therapeutics Inc COM | $2.7M | 551.7K | 2.0% | ▼−23% Reduced · −162K sh | |
| 17 | Xilio Therapeutics Inc COM | $2.2M | 226.0K | 1.6% | ▲+252% Added · +162K sh | |
| 18 | Adicet Bio Inc COM NEW | $2.1M | 245.5K | 1.6% | ▲+11% Added · +24K sh | |
| 19 | Tela Bio Inc COM | $2.0M | 2.66M | 1.5% | ▲+1.7% Added · +45K sh | |
| 20 | Aytu Biopharma Inc COM | $2.0M | 912.9K | 1.5% | ▲+15% Added · +121K sh | |
| 21 | Curis Inc COM | $1.7M | 3.31M | 1.3% | ▼−11% Reduced · −414K sh | |
| 22 | Spruce Biosciences Inc COM NEW | $1.6M | 28.8K | 1.2% | ▲New New position | |
| 23 | Okyo Pharma Ltd SHS NEW | $1.3M | 863.0K | 1.0% | ▲+1.5% Added · +13K sh | |
| 24 | Pasithea Therapeutics Corp COM NEW | $1.1M | 2.20M | 0.9% | ▲+165% Added · +1.4M sh | |
| 25 | Sol-Gel Technologies Ltd SHS NEW | $1.1M | 14.5K | 0.8% | ▼−48% Reduced · −13K sh | |
| 26 | Pulmonx Corp COM | $1.1M | 815.4K | 0.8% | ▲+6.1% Added · +47K sh | |
| 27 | X4 Pharmaceuticals Inc COM NEW | $1.1M | 225.0K | 0.8% | ▼−33% Reduced · −110K sh | |
| 28 | In8bio Inc COM NEW | $980K | 695.3K | 0.7% | ▲+4.8% Added · +32K sh | |
| 29 | Moonlake Immunotherapeutics CLASS A ORD | $974K | 50.0K | 0.7% | ▲New New position | |
| 30 | Quoin Pharmaceuticals Ltd SPONSORED ADS | $966K | 199.5K | 0.7% | ▲+273% Added · +146K sh | |
| 31 | Maxcyte Inc COM | $924K | 751.6K | 0.7% | ▼−25% Reduced · −253K sh | |
| 32 | Phathom Pharmaceuticals Inc COM | $922K | 85.0K | 0.7% | ▲+70% Added · +35K sh | |
| 33 | Azitra Inc COM NEW | $887K | 5.29M | 0.7% | ▲New New position | |
| 34 | Connect Biopharma Hldgs Ltd SHS | $867K | 364.3K | 0.7% | ▲+18% Added · +54K sh | |
| 35 | Cybin Inc COM NEW | $855K | 129.3K | 0.7% | ▼−3.6% Reduced · −5K sh | |
| 36 | Ultragenyx Pharmaceutical In COM | $835K | 25.0K | 0.6% | ▲New New position | |
| 37 | Inhibikase Therapeutics Inc COM NEW | $804K | 396.2K | 0.6% | ▼−59% Reduced · −561K sh | |
| 38 | Zentalis Pharmaceuticals Inc COM | $784K | 161.6K | 0.6% | ▼−40% Reduced · −108K sh | |
| 39 | Cytomx Therapeutics Inc. COM | $769K | 205.0K | 0.6% | ▲+2.5% Added · +5K sh | |
| 40 | Nuvectis Pharma Inc COM | $736K | 40.0K | 0.6% | ▲New New position | |
| 41 | Crescent Biopharma Inc. COM | $720K | 40.0K | 0.5% | ▼−53% Reduced · −45K sh | |
| 42 | PMV Pharmaceuticals Inc COM | $718K | 536.1K | 0.5% | ▼−24% Reduced · −172K sh | |
| 43 | Oruka Therapeutics Inc COM | $714K | 7.5K | 0.5% | ▲New New position | |
| 44 | Radiopharm Theranostics Ltd SPONSORED ADS | $671K | 51.00M | 0.5% | —Held | |
| 45 | Onkure Therapeutics Inc COM CL A | $596K | 130.7K | 0.5% | ▼−1.4% Reduced · −2K sh | |
| 46 | Nervgen Pharma Corp COM | $560K | 271.7K | 0.4% | ▲New New position | |
| 47 | Calcimedica Inc COM NEW | $545K | 622.4K | 0.4% | ▲New New position | |
| 48 | Arvinas Inc COM | $499K | 60.0K | 0.4% | ▲+118% Added · +33K sh | |
| 49 | Bioage Labs Inc COM | $490K | 20.0K | 0.4% | ▼−60% Reduced · −30K sh | |
| 50 | Opus Genetics Inc COM | $414K | 100.7K | 0.3% | ▲+47% Added · +32K sh |
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1440771/holdings"
Use Arkolith to show Stonepine Capital Management, LLC's latest holdings, largest changes, and filing provenance.
Put / call positions from the 13F — totals include every disclosed option leg
| Type | Underlying | Notional value | Underlying shares |
|---|---|---|---|
| CALL · bullish | ADMA BIOLOGICS INCADMA | $8.0M | 650K |
| CALL · bullish | INSMED INCINSM | $5.6M | 40K |
| CALL · bullish | ULTRAGENYX PHARMACEUTICAL INRARE | $5.5M | 200K |
| CALL · bullish | MEDTRONIC PLCMDT | $4.4M | 50K |
| CALL · bullish | ABBOTT LABORATORIESABT | $3.8M | 40K |
| CALL · bullish | BOSTON SCIENTIFIC CORPBSX | $3.3M | 50K |
| CALL · bullish | EVOLUS INCEOLS | $3.1M | 420K |
| CALL · bullish | BIOMARIN PHARMACEUTICAL INCBMRN | $3.1M | 50K |
| CALL · bullish | XERIS BIOPHARMA HOLDINGS INCXERS | $2.1M | 280K |
| CALL · bullish | SI-BONE INCSIBN | $1.5M | 100K |
| CALL · bullish | HERON THERAPEUTICS INCHRTX | $1.5M | 1.0M |
| CALL · bullish | NEUMORA THERAPEUTICS INCNMRA | $1.3M | 500K |
| CALL · bullish | ARDELYX INCARDX | $1.1M | 150K |
| CALL · bullish | DELCATH SYSTEMS INCDCTH | $1.0M | 100K |
| CALL · bullish | MANNKIND CORPMNKD | $750K | 250K |
13F filers disclose option positions at the market value of the underlying the contracts reference, not the premium paid. A put is a bearish bet (it gains if the stock falls); a call is bullish. “Underlying shares” is the share count the contracts control, not a share holding. These legs are excluded from the equity book, weighting, concentration and sector figures above.
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | Aug 17, 2026 | 87 | $177.3M | 13F-HR/A |
| Q1 2026 | Mar 31, 2026 | May 14, 2026 | 83 | $249.7M | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 13, 2025 | 58 | $123.0M | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 13, 2025 | 59 | $101.9M | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 14, 2025 | 66 | $102.8M | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 14, 2025 | 52 | $123.9M | 13F-HR |
| Q3 2024 | Aug 21, 2024 | Aug 21, 2024 | 25 | $109.6M | 13F-HR/A |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. The performance line is a simulation of the disclosed long book, not an audited return.